• All Courts
  • Federal Courts
  • Bankruptcies
  • PTAB
  • ITC
Track Search
Export
Download All
Active Filters1
Displaying 39-53 of 311 results

12 Notice: Patent Owner Neurelis Incs Mandatory Change of Information Notices

Document IPR2019-00451, No. 12 Notice - Patent Owner Neurelis Incs Mandatory Change of Information Notices (P.T.A.B. Sep. 5, 2019)
Case IPR2019-00451 Patent No. 9,763,876 Pursuant to 37 C.F.R. § 42.8(a)(3), the undersigned on behalf of and acting in a representative capacity for Patent Owner Neurelis, Inc. (Patent Owner), hereby submits the following mandatory change-of-information notices in connection with the petition for inter partes review identified in the caption.
Date: 5 September 2019
Respectfully submitted, /Richard Torczon/ Richard Torczon Reg. No. 34,448 Case IPR2019-00451 Patent No. 9,763,876
cite Cite Document
Analyze

10 Rehearing Request in re Petition Institution Decision Denied: Neurelis, Inc Request for Rehearing

Document IPR2019-00451, No. 10 Rehearing Request in re Petition Institution Decision Denied - Neurelis, Inc Request for Rehearing (P.T.A.B. Aug. 27, 2019)
The Federal Circuit has explained that “the description must ‘clearly allow persons of ordinary skill in the art to recognize that [the inventor] invented what is claimed.’” Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., 598 F.3d 1336, 1351 (Fed. Cir. 2010) (en banc), quoting Vas-Cath Inc. v. Mahurkar, 935 F.2d 1555, 1562-63 (Fed. Cir. 1991).
By sua sponte adding an extra-legal requirement for priority, the decision misapprehends the proper scope of the test and legally errs, significantly prejudicing Neurelis.
1348, 1356-57, 1360 (2018).2 Indeed, the rule itself does not 2 In Atmel Corp. v. Information Storage Devices, Inc., the court in dicta considered whether incorporation might be inappropriate for the corresponding structure of a means-plus-function claim, but ultimately held that the specification had sufficient
As noted previously, a Rule 57(h) requirement begins with the Office setting a time for response bounded by close of prosecution or abandonment, neither of which apply to a provisional application.
The formal objection raised sua sponte in the decision misapprehends a patentee’s legal obligations and the scope of the invoked rule, and overlooks contrary case law, Office guidance, and due-process requirements.
cite Cite Document
Analyze

11 Objection: Neurelis, Inc Objections

Document IPR2019-00451, No. 11 Objection - Neurelis, Inc Objections (P.T.A.B. Aug. 27, 2019)
The exhibit’s probative value is substantially outweighed by its confusion of the issues to be decided, its waste of Board and Neurelis time, and the danger that it will lead to unfair prejudice if used later in the proceeding or on appeal.
The exhibit’s probative value is substantially outweighed by its confusion of the issues to be decided, its waste of Board and Neurelis time, and the danger that it will lead to unfair prejudice if used later in the proceeding or on appeal.
The exhibit’s probative value is substantially outweighed by its confusion of the issues to be decided, its waste of Board and Neurelis time, and the danger that it will lead to unfair prejudice if used later in the proceeding or on appeal.
The exhibit’s probative value is substantially outweighed by its confusion of the issues to be decided, its waste of Board and Neurelis time, and the danger that it will lead to unfair prejudice if used later in the proceeding or on appeal.
The exhibit’s probative value is substantially outweighed by its confusion of the issues to be decided, its waste of Board and Neurelis time, and the danger that it will lead to unfair prejudice if used later in the proceeding or on appeal.
cite Cite Document
Analyze

6 Notice: Patent Owners Mandatory Notices

Document IPR2019-00451, No. 6 Notice - Patent Owners Mandatory Notices (P.T.A.B. May. 21, 2019)
The patent owner provides the following notice pursuant to 37 CFR §42.8(a)(2).
Real parties-in-interest [no change] Neurelis, Inc. (“Neurelis”) owns the involved patent.
Related matters [no change] The petitioner has filed two additional inter partes review petitions (IPR2019-00449 and IPR2019-00450) against the involved patent.
Neurelis has an application (15/470,498) that claims benefit under 35 U.S.C. 120 to the application that issued as the involved patent.
Date: 21 May 2019 /Richard Torczon/ Richard Torczon Reg. No. 34,448
cite Cite Document
Analyze

7 Preliminary Response: Patent Owner Preliminary Response

Document IPR2019-00451, No. 7 Preliminary Response - Patent Owner Preliminary Response (P.T.A.B. May. 21, 2019)

cite Cite Document
Analyze

4 Mandatory Notice: Patent Owners Mandatory Notices

Document IPR2019-00451, No. 4 Mandatory Notice - Patent Owners Mandatory Notices (P.T.A.B. Feb. 19, 2019)

cite Cite Document
Analyze

1 Power of Attorney: Power of Attorney

Document IPR2019-00451, No. 1 Power of Attorney - Power of Attorney (P.T.A.B. Jan. 29, 2019)

cite Cite Document
Analyze

2026 Exhibit: Affidavit of Ronald Figueroa

Document IPR2019-00451, No. 2026-158 Exhibit - Affidavit of Ronald Figueroa (P.T.A.B. Apr. 28, 2020)

cite Cite Document
Analyze

2030 Exhibit: J Wyse, US Patent No 9,192,570 issued November 24, 2015

Document IPR2019-00451, No. 2030-154 Exhibit - J Wyse, US Patent No 9,192,570 issued November 24, 2015 (P.T.A.B. Mar. 10, 2020)

cite Cite Document
Analyze

1070 Exhibit: Gizurarson, Patent Application Publication No US 20080275030, Nov...

Document IPR2019-00451, No. 1070-96 Exhibit - Gizurarson, Patent Application Publication No US 20080275030, Nov 6, 2008 (P.T.A.B. Jan. 28, 2020)

cite Cite Document
Analyze

1119 Exhibit: Davis GA, Rudy AC, Archer SA, Wermeling DP, McNamara PJ Effect o...

Document IPR2019-00451, No. 1119-123 Exhibit - Davis GA, Rudy AC, Archer SA, Wermeling DP, McNamara PJ Effect of fluticasone propionate nasal spray on bioavailability of hydromorphone hydrochlo...

cite Cite Document
Analyze

1082 Exhibit: Chien, YW, et al, Nasal Systemic Drug Delivery, Chapter 1, Anatomy a...

Document IPR2019-00451, No. 1082-104 Exhibit - Chien, YW, et al, Nasal Systemic Drug Delivery, Chapter 1, Anatomy and Physiology of the Nose, Drugs and the Pharmaceutical Sciences, Vol 39, Marcel ...

cite Cite Document
Analyze

1129 Exhibit: Burstein AH, Modica R, Hatton M, et al Pharmacokinetics and pharma...

Document IPR2019-00451, No. 1129-130 Exhibit - Burstein AH, Modica R, Hatton M, et al Pharmacokinetics and pharmacodynamics of midazolam after intranasal administration J Clin Pharmacol 1997 37 7...

cite Cite Document
Analyze

1135 Exhibit: Greenblatt D, Gan L, Harmatz, et al Pharmacokinetics and pharmaco...

Document IPR2019-00451, No. 1135-134 Exhibit - Greenblatt D, Gan L, Harmatz, et al Pharmacokinetics and pharmacodynamics of single dose triazolam EEG compared with digital symbol substitution te...

cite Cite Document
Analyze

1144 Exhibit: Ahmad S, Ellis J, Kamwendo H, et al Efficacy and safety of intranasal...

Document IPR2019-00451, No. 1144-143 Exhibit - Ahmad S, Ellis J, Kamwendo H, et al Efficacy and safety of intranasal lorazepam versus intramuscular paraldehyde for protracted convulsions in children...

cite Cite Document
Analyze
<< 1 2 3 4 5 6 7 ... >>